Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial

1. Motzer, R.J.
2. Escudier, B.
3. George, S.
4. Hammers, H.J.
5. Srinivas, S.
6. Tykodi, S.S.
7. Sosman, J.A.
8. Plimack, E.R.
9. Procopio, G.
10. McDermott, D.F.
11. Castellano, D.
12. Choueiri, T.K.
13. Donskov, F.
14. Gurney, H.
15. Oudard, S.
16. Richardet, M.
17. Peltola, K.
18. Alva, A.S.
19. Carducci, M.
20. Wagstaff, J.
21. Chevreau, C.
22. Fukasawa, S.
23. Tomita, Y.
24. Gauler, T.C.
25. Kollmannsberger, C.K.
26. Schutz, F.A.
27. Larkin, J.
28. Cella, D.
29. McHenry, M.B.
30. Saggi, S.S.
31. Tannir, N.M.
32. Show all authors +